Metrizamide as contrast medium for myelography and ventriculography. Preliminary clinical experiences.
D014695:Cerebral Ventriculography / Q000379:methods; D003287:Contrast Media / Q000009:adverse effects* / Q000378:metabolism; D004361:Drug Tolerance; D004569:Electroencephalography; D004576:Electromyography; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007463:Iodobenzoates / Q000009:adverse effects*; D007482:Iothalamate Meglumine / Q000009:adverse effects; D008793:Metrizamide / Q000009:adverse effects* / Q000378:metabolism; D009192:Myelography / Q000379:methods; D009325:Nausea / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D003287:Contrast Media; D007463:Iodobenzoates; D008793:Metrizamide; D007482:Iothalamate Meglumine